Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blinded (placebo) Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Progesterone (17P, Makena®) for Prolongation of Pregnancy in Women With Preterm Rupture of the Membranes (PROM)

NCT01119963
View directory record Official record
Conditions
Preterm Delivery
Interventions
17-alpha-hydroxy-progesterone caproate, Makena®, Castor Oil (Placebo)
Drug
Lead sponsor
Obstetrix Medical Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
15
States / cities
Mobile, Alabama • Mesa, Arizona • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 2Phase 3 Interventional Results available

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00463567
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions
Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
2,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
221
States / cities
Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 2 Interventional

Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

NCT00882258
View directory record Official record
Conditions
Uterine Fibroids
Interventions
12.5 mg Proellex, 25 mg Proellex, Placebo
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tuscon, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 3 Interventional

ACTIV-3: Therapeutics for Inpatients With COVID-19

NCT04501978
View directory record Official record
Conditions
Covid19
Interventions
LY3819253, Placebo, Remdesivir, VIR-7831, BRII-196/BRII-198, AZD7442, MP0420, PF-07304814
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
2,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
98
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2023 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Interaction Between TMP-301 and Cocaine.

NCT06648668
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
TMP-301, Placebo
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

NCT02392624
View directory record Official record
Conditions
Urticaria
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
40
States / cities
Granada Hills, California • Long Beach, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 29, 2026, 1:48 AM EDT
Terminated Not applicable Interventional Results available

Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer

NCT00217724
View directory record Official record
Conditions
Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
glutamine, placebo
Dietary Supplement · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 29, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371
View directory record Official record
Conditions
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg), Placebo to match CK-4021586
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
40 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
26
States / cities
Fairhope, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 29, 2026, 1:48 AM EDT
Not yet recruiting Phase 1 Interventional

OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis

NCT07221799
View directory record Official record
Conditions
Multiple Sclerosis, Neuropathic Pain
Interventions
glibenclamide, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Trial of PRAX-944 in Participants With Essential Tremor

NCT05021978
View directory record Official record
Conditions
Essential Tremor
Interventions
Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944, Part B: 120 mg PRAX-944 and Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Port Charlotte, Florida • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes

NCT05511818
View directory record Official record
Conditions
Sleep, Sleep Disturbance, Sleep Disorder
Interventions
Rest Study Product Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
2,679 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 29, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

NCT07467993
View directory record Official record
Conditions
Schizophrenia
Interventions
GXV813, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Bentonville, Arkansas • Pico Rivera, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 29, 2026, 1:48 AM EDT
No Longer Available No phase listed Expanded access

Pulmonary Vein Isolation Outcomes With Fish Oils

NCT00841451
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Lovaza (Fish Oils)
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older
U.S. locations
3
States / cities
Ridgewood, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 29, 2026, 1:48 AM EDT
Terminated Phase 3 Interventional

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

NCT05263999
View directory record Official record
Conditions
Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
Interventions
Itolizumab, EQ001 Placebo
Biological · Drug
Lead sponsor
Equillium
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 29, 2026, 1:48 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Lorazepam Effects on Neuroimaging Measures

NCT04671836
View directory record Official record
Conditions
Lorazepam, Neuroimaging
Interventions
Lorazepam 1Mg Tablet, Placebo
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 29, 2026, 1:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Comparison of a Drug and Placebo in the Prevention of Migraine Headaches

NCT01122381
View directory record Official record
Conditions
Headache, Migraine
Interventions
ethosuximide, placebo comparator
Drug · Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 29, 2026, 1:48 AM EDT
Recruiting Phase 2Phase 3 Interventional

Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study

NCT07001800
View directory record Official record
Conditions
Moderate Aortic Valve Stenosis
Interventions
Ataciguat, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Not applicable Interventional

A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders

NCT01765309
View directory record Official record
Conditions
Breast Cancer
Interventions
Bilateral mastectomy with reconstruction
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 29, 2026, 1:48 AM EDT
Withdrawn Phase 2 Interventional

Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma

NCT01304628
View directory record Official record
Conditions
Asthma
Interventions
PL-3994
Drug
Lead sponsor
Palatin Technologies, Inc
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Cranbury, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness

NCT03077919
View directory record Official record
Conditions
PostTraumatic Stress Disorder
Interventions
Ropivacaine, Sham treatment
Drug
Lead sponsor
RTI International
Other
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Honolulu, Hawaii • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

NCT01290419
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV-F Particle Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)

NCT00900731
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol, Placebo to tiotropium
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
25
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 29, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427

NCT04630067
View directory record Official record
Conditions
Heart Failure
Interventions
AZD3427, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Little Rock, Arkansas • Glendale, California • Daytona Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 29, 2026, 1:48 AM EDT